Full Name
Jennifer Carter, MD, MPH
Job Title
Founder and CEO
Company
Medzown, Inc.
Speaker Bio
Dr. Jennifer Levin Carter, MD, MPH, MBA, is Founder and CEO of Medzown, Inc, a precision medicine management company. Medzown’s mission is to help each individual fighting cancer, rare diseases, and other complex diseases get better, faster access to cutting- edge treatments while aligning the incentives of payers, pharma, and providers so that all stakeholders save money. These patients account for over 1/3 of total healthcare spend.
She has an extensive background as a healthcare executive, investor, board member, and entrepreneur, with a proven track record in innovative strategies and solutions at the intersection of healthcare IT, digital health, machine learning, and precision medicine.
Prior to Medzown, Dr. Carter was a Managing Partner and Venture Partner at Sandbox Industries and Blue Venture Fund—a collaboration between BCBS companies, BCBSA, and Sandbox, focusing on healthcare, technology, and clinical investments.
Dr. Carter was the Founder and President of N-of-One, Inc., leading as CEO and later as President and Chief Medical Officer, developing precision medicine solutions that transformed patient access to cancer treatments globally. N-of-One was acquired by Qiagen in 2019. At N-of-One, Dr. Carter led the creation of award-winning solutions that still deliver novel treatment strategies to hundreds of thousands of patients with cancer globally. Dr. Carter also founded a novel clinical trials company, which was acquired by Integral (Valo) Health, a Flagship Pioneering company in March 2019.
Dr. Carter serves on multiple public, private, and not-for-profit Boards of Directors. She is recognized as a leading expert and speaker, contributing to numerous conferences and symposiums while serving on various industry advisory boards. Her contributions to the field have positioned her as a formidable leader in reimagining healthcare through precision medicine.
Dr. Carter holds a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School of Management at MIT.
She has an extensive background as a healthcare executive, investor, board member, and entrepreneur, with a proven track record in innovative strategies and solutions at the intersection of healthcare IT, digital health, machine learning, and precision medicine.
Prior to Medzown, Dr. Carter was a Managing Partner and Venture Partner at Sandbox Industries and Blue Venture Fund—a collaboration between BCBS companies, BCBSA, and Sandbox, focusing on healthcare, technology, and clinical investments.
Dr. Carter was the Founder and President of N-of-One, Inc., leading as CEO and later as President and Chief Medical Officer, developing precision medicine solutions that transformed patient access to cancer treatments globally. N-of-One was acquired by Qiagen in 2019. At N-of-One, Dr. Carter led the creation of award-winning solutions that still deliver novel treatment strategies to hundreds of thousands of patients with cancer globally. Dr. Carter also founded a novel clinical trials company, which was acquired by Integral (Valo) Health, a Flagship Pioneering company in March 2019.
Dr. Carter serves on multiple public, private, and not-for-profit Boards of Directors. She is recognized as a leading expert and speaker, contributing to numerous conferences and symposiums while serving on various industry advisory boards. Her contributions to the field have positioned her as a formidable leader in reimagining healthcare through precision medicine.
Dr. Carter holds a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School of Management at MIT.
Speaking At
